Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 11,253 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Sickle Cell Disease, Pulmonary Hypertension
Interventions: Hydroxyurea; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 10 Years to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Congenital Heart Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1980 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fabry Disease
Interventions: Replagal; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: PF-07275315, PF-07264660, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 50
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 42 more

Conditions: Image Evaluation
Interventions: 3.0 T Neonatal MRI Scanner; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: Up to 2 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Regional Saturation of Oxygen (rSO2)
Interventions: Masimo O3 Neonatal Sensors, 510(k) cleared sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: Up to 28 Days
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Vestibular Schwannoma, Neurofibromatosis Type 2
Interventions: bevacizumab, laboratory biomarker analysis, quality-of-life assessment; Biological · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • Rockville, Maryland • Charlestown, Massachusetts

Conditions: Rett Syndrome
Interventions: None interventional; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimer Disease, Huntington Disease
Interventions: digoxin, dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gaucher's Disease Type III
Interventions: Venglustat, imiglucerase; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: New Haven, Connecticut • Iowa City, Iowa • Dallas, Texas + 1 more

Conditions: Post-operative Pain, Opioid Use, Cleft Palate
Interventions: Quadratus lumborum block, Local anesthetic infiltration; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Years to 18 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
Interventions: ABO-102; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prader Willi Syndrome, Obsessive-compulsive Disorder
Interventions: Cognitive-behavioral therapy, Wait-list control; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Neonatal Opioid Withdrawal Syndrome
Interventions: Not listed
Lead sponsor: Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program; Network
Eligibility: Up to 1 Month
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Durham, North Carolina + 3 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Dayton Children's Hospital; Other
Eligibility: 7 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Healing Wound, Alveolar; Wound, Alveolar Bone Loss, Image, Dent Disease
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
Interventions: Clinical Decision Support; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1,543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions: PBGM01; Biological
Lead sponsor: Gemma Biotherapeutics; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more

Conditions: Hypothyroidism, Trisomy 21
Interventions: Liquid stable levothyroxine (L-T4) Tirosint-SOL, Oral tablet levothyroxine (L-T4); Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Months to 4 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Contraceptive Usage, Opioid Dependence
Interventions: Treatment as usual, WHO contraception protocol, Incentives; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Pulmonary Hypertension of Newborn
Interventions: INOmax; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 27 Weeks to 40 Weeks
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Pompe Disease
Interventions: ATB200, AT2221; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Gainesville, Florida + 9 more

Conditions: Severe Hemophilia A
Interventions: Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab, Eloctate ITI; Drug
Lead sponsor: Margaret Ragni; Other
Eligibility: 4 Months to 99 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sleep Apnea, Obesity
Interventions: Not listed
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening

Dosing Study of Replagal in Patients With Fabry Disease

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit

Performance Comparison of Masimo O3 Regional Oximetry Sensors in Neonates

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Cognitive Function in Rett Syndrome During Trofinetide Treatment

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

QL vs LAI for Palatoplasty

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project

ACT NOW Longitudinal Study: Outcomes of Babies With Opioid Exposure Study

Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

Ultrasound for Socket Healing Evaluation

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients

Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

Sleep Apnea in Pregnancy Screening Study